The high cost of heart failure for the Medicare population: An actuarial cost analysis

Major efforts to improve the care and reduce the cost of heart failure patients have recently been implemented. Despite these efforts, however, the rate of heart failure is rising and only small improvements in survival have been realized. The lack of novel therapies and limited improvement in medical management highlight the need for more focus on heart failure, especially among the Medicare population.

This report was commissioned by Novartis Pharmaceuticals.